Gevokizumab plus standard of care anti-cancer therapies for metastatic colorectal cancer, gastroesophageal cancer and renal cell carcinoma.
Phase 1
Completed
- Conditions
- - metastatic colorectal cancer- gastroesophageal cancer- renal cell carcinoma
- Registration Number
- JPRN-jRCT2080224642
- Lead Sponsor
- ovartis Pharma. K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Metastatic disease not amenable to potentially curative surgery and with available archival tumor tissue or fresh tumor tissue biopsy.
Exclusion Criteria
- Currently receiving any of the prohibited medications or has contraindications as outlined in the Contraindications to SOC regimen components.
- Symptomatic brain metastases or brain metastases that require directed therapy (such as focal radiotherapy or surgery).
- Suspected or proven immunocompromised state, or infections.
- Conditions that have a high risk of clinically significant bleeding after administration of anti-VEGF agents.
- Clinically significant, uncontrolled cardiovascular disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method